Copy
MabDesign News 
Newsletter n°9 -December 8th, 2016
View this email in your browser
In this Issue:
 
Join us at our next scientific event in Marseille, Dec. 20th 2016 on preclinical development of immunotherapies.

Moreover, we have developed special for you a new service :  Business Intelligence. Check it out!

Read the zoom on the MabDesign member PROMISE Advanced Proteomics.

Also take a loot at the upcoming events to book your Agenda!


Finally read the latest news about MabDesign Members !
 
Wish you good reading,
MabDesign Team
Speakers already confirmed !
  • Jean-Philippe Coton, Chief Executive Officer, Histalim 
  • Alexis Roussignol, R&D Project Manager, Clean Cells
  • Agnès Menut, Program Manager and Business development, Mi-mAbs
  • Mona Boyé, Scouting and Program Manager, Ksilink
  • Philippe Ancian, Directeur Biomarker, CitoxLab
  • Jean Viallet, Chief Executive Officer, Inovotion
  • Luc Barraud, Head of Assays and Imaging Laboratory, Transgene
  • Sébastien Tabruyn, Chief Scientific Officer, Transcure  bioServices
  • Hugues Contamin, Chief Executive Officer, Cynbiose
  • Serge Desmoulins, Product Specialist Automation Solutions,  Agilent Technologies
  • François Lachapelle, Directeur Scientifique, AnimAlliance
  • Ana Zarubica,  Chief Operating Officer, CIPHE- Centre d’Immunophenomique
Register Now !

l
MabDesign’s Business Intelligence Service
Do you have questions about Intellectual Property relating to your scientific projects ?
 
MabDesign has created a new Business Intelligence Service to help its members to solve their Intellectual property issues.   
To know all about the services that MabDesign can supply you in different areas of Intellectual Property download now the pdf document !
Business Intelligence Service
ZOOM ON ... PROMISE  Advanced Proteomics
Biotherapeutics development: go further and faster with PROMISE

Since 2010, PROMISE supports pharmaceutical companies in the development of their biotherapeutics. By providing them with a cutting edge technology, we make fast and cost effective pharmacokinetic studies possible, without developing any capture antibody. It’s a gain of time and money, especially suited for early phase development.
The development of a novel biotherapeutic product is a long, challenging and costly process, during which the choice of competent partners and technologies is crucial.
 
At any stage of a project (proof of concept, candidate selection,
PK studies…), consider PROMISE solutions!
 
Contact us to discuss your project: our ambition is to provide you with an optimal and customized solution to make it succeed. Contact PROMISE
UPCOMING EVENTS
Dév. Préclinique des immunotérapies - Dec. 20 - Marseille
Registration and BtoB meetings set-up are open ! 
SAVE THE DATE
Immuno-conjugués pour la médecine personnalisée  - Fev. 9, 2017 - Nantes
Co-organisé par MabDesign et Atlanpole Biotherapies.
 
Venez découvrir les dernières innovations en matière d'immuno-conjugués comme outils pour la thérapie, le diagnostic, l’immunomonitorage ou le développement  de companion diagnostics, dans une optique de médecine personnalisée.
World ADC Berlin
20-23 February 2017, Berlin

www.worldadc-europe.com/
 
Bringing together 60+ thought leaders in the ADC field; you will hear their lessons learned, discuss new data and debater future opportunities.
MabDesign members have an exclusive 20% discount on the registration fees.
Contact us to obtain the code !
Next Gen Immuno-Oncology Congress
London - 14-15 March 2017
This congress brings together  academicians, researcher and scientist to discuss the growth of current therapeutics and pave way for emerging next generation therapeutics.
MabDesign members have an exclusive 20% discount on registration fees.
Contact us to receive the discount code !
New for AIS2017 : Innovation Area
Are you a small biotech that has developed a new innovation and would like to
showcase your product/technology in an international congress?


Here is your opportunity ! Apply for the Innovation Area (limited places available)

To know more about it download the Sponsor & Exhibition kit.
Sponsor & Exhibition Opportunities
OUR  MEMBERS
More than 70 companies have already joined MabDesign!

Do you know them?

 
I ABL Lyon I ABLIANCE I ACANTHE BIOTECH I  ACCINOV  I  ACTICOR BIOTECH  I ADVANCED BIODESIGN  I  AGILENT  I  AGUETTANT BIOTECH ANAQUANTANTINEO  I ATLANBIO I  ATLANPOLE BIOTHERAPIES  I  AXENIS  I B CELL DESIGNBIOCELLCHALLENGE  I  BIOMUNEX  I BIOTEM  I  BLINKBIOMEDICAL I  CALIXAR I CAMINNOV  I CANCER BIO SANTÉ  I  CARLINA TECH  I  CELLENION  I CISBIOCLEAN CELLS  I  COVALAB  I C.RIS PHARMA I DELPHARM BIOTECH  I  DENDRITICS  I  DYNABIO SA   I  ECRINS THERAPEUTICS  I EIVATECHELSALYS BIOTECH  I ENSTBB  I  EUROBIOMED  I  FAB'ENTECH I GE HEALTHCARE  I GENEPEP  I  GENOWAY  I   GENTICEL  I  GLYCODIAG  I  GROUPE IMT  I  GTP TECHNOLOGY  I  HISTALIM  I  HYBRIGENICS SERVICES  I  IDD  I  IDD BIOTECH  I  INOVOTION  I  INSTITUT DE RECHERCHE PIERRE FABRE  I  LFB BIOTECHNOLOGIES  I LXREPAIR  I LYONBIOPOLE  I MAAT PHARMAMC SAF  I  MEDICEN PARIS REGION  I  MERCK BIODEVELOPMENT  I  MIMABS  I  NETRIS PHARMA  I  NOVADISCOVERY  I  NOVASEP  I  OGD2 PHARMA  I  OSE IMMUNOTHERAPEUTICS I PROMISE ADVANCED PROTEOMICS  I PROTEODYNAMICS  I  PX*THERAPEUTICS  I  RD BIOTECH  I  REPROPHARM  I  SANOFI  I  SIAMED’XPRESS  I     SYCOMORE TECHNOLOGIES  I  SYNDIVIA  I  SYNTHELIS  I TEBU-BIO  I  VETOQUINOL  I  VIBIOSPHEN  I VIROSCAN3D I VOXCAN
NEWS ABOUT OUR MEMBERS
December 8, 2016 - Sanofi et Regeneron anoncent que l'EMA a accepté l'examen de la demande d'authorisation de mise sur le marché de Dupixent  (dupilumab). Read more

December 7, 2016 - Inovotion, one of the three "stars", winners of the 2016 R2B Onco Trophies. Read more

December 5, 2016 - Hybrigenics : résultats in vitro approfondis sur l'inécalcitol dans le myélome multiple et la leucémie myéloïde aigüe. Read more

December 1, 2016 – BIOTEM est désormais certifiée ISO 13485:2012 pour ses activités de développement, fabrication et commercialisation d’immunoessais pour le diagnostic in vitro. Read more
 
November 29, 2016 – OGD2 Pharma and University Hospital of Zurich start collaboration on Innovative immunotherapy in brain cancer. Read more


November 29, 2016 - Accinov and Biodextris team up to provide a unique contract development and manufacturing service package. Read more
 
November 28, 2016 – OSE Immunotherapeutics nomme le Dr. Frédérique Corallo au poste de Directeur Médical Immunologie. Read more
 
November 24, 2016 – VRI, ANRS and Novasep sign an agreement for the cGMP manufacture of two experimental vaccines for the prevention and treatment of HIV-1/AIDS. Read more


November 24, 2016 - Hervé Affagard, CEO and Co-Founder of MaaT Pharma has been awarded the Prize of Health Entrepreneur 2016 by France Biotech. Read more

November 24, 2016 - GTP Technology and Novasep have been selected by VRI and ANRS for the production of 2 candidate vaccines against HIV. Read more

November 21, 2016 - CALIXAR published new article on novel Biotinylated Membranes Solubilization and Separation method (BMSS). Read more

November 17, 2016 – OSE Immunotherapeutics annonce la publication en ligne des résultats cliniques positifs de phase 1 du FR104 dans « Journal of Immunology ». Read more

November 17, 2016 – Sanofi et Regeneron annoncent que l’essai clinique évaluant les bénéfices de Praluent®(alirocumab) sur le risque d’événements cardiovasculaires continuera comme prévu à l’issue de l’analyse intermédiaire. Read more

November 16, 2016 -Stroke company Acticor Biotech and Mediolanum announce a Research Collaboration Agreement. Read more
 
November 3, 2016 - Ecrins Therapeutics est pré-sélectionnée pour les trophées de l’innovation organisés par BrefEco le 7 Novembre. Read more


November 1, 2016 – Biotem : Ultimate Humanization® : vers une nouvelle ère des anticorps thérapeutiques. BIOTEM et LaBiotech ce sont associées pour la publication d'un article sur l'innovation en matière de développement d'anticorps thérapeutiques. Read more
NEWS AROUND THE WORLD
 
December 8, 2016 -Compugen Discloses its Cancer Immunotherapy Program Targeting TIGIT Immune Checkpoint. Read more

December 8, 2016- Second CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpoints in Patients with Moderate-to-Severe Chronic Plaque Psoriasis. Read more

 
December 7, 2016 - NOXXON PHARMA annonce de nouvelles données précliniques mettant en évidence une synergie entre NOX-A12 et les thérapies utilisant les cellules tueuses naturelles NK. Read more.


December 7, 2016 - Transgene: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC). Read more

December 7, 2016 - FDA Approves Genentech’s Avastin® (Bevacizumab) Plus Chemotherapy for a Specific Type of Advanced Ovarian Cancer. Read more

December 6, 2016 - Immunomedics Introduces New Antibody-Drug Conjugate at Annual Meeting of American Society of Hematology. Read more

December 5, 2016 - Another Pharma sloughs off Small Molecules to focus on Biologics. Read more

December 5, 2016 - Sanofi Genzyme Announces Start of Phase III Study of Isatuximab for Relapsed and Refractory Multiple Myeloma. Read more

November 29, 2016 – Merck : FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review. Read more

Read more News on Antibodies : PipelineReview
Copyright © 2016 - MabDesign, All rights reserved.